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A B S T R A C T
Innate lymphoid cells (ILC) including NK cells (cytotoxic) and the recently identified “helper” ILC1, ILC2 and
ILC3, play an important role in innate defenses against pathogens. Notably, they mirror analogous T cell subsets,
regarding the pattern of cytokine produced, while the timing of their intervention is few hours vs days required
for T cell-mediated adaptive responses. On the other hand, the effectiveness of ILC in anti-tumor defenses is
controversial. The relevance of NK cells in the control of tumor growth and metastasis has been well documented
and they have been exploited in the therapy of high risk leukemia in the haploidentical hematopoietic stem cell
transplantation setting. In contrast, the actual involvement of helper ILCs remains contradictory. Thus, while
certain functional capabilities of ILC1 and ILC3 may favor anti-tumor responses, other functions could rather
favor tumor growth, neo-angiogenesis, epithelial-mesenchymal transition and metastasis. In addition, ILC2, by
secreting type-2 cytokines, are thought to induce a prevalent pro-tumorigenic effect. Finally, the function of both
NK cells and helper ILCs may be inhibited by the tumor microenvironment, thus adding further complexity to the
interplay between ILC and tumors.
1. Introduction
Natural Killer cells play an important role in innate defenses against
cancer and viral infections. Their constitutive storage of perforin and
granzymes as well as the rapid production of IFN-γ and TNF-α upon cell
triggering, allows their prompt intervention against tumor cells and
favors the initiation of inflammation [1–5]. NK cells are regulated by an
array of receptors mediating either inhibitory or activating signals that
finely tune their function [6–8]. In humans, important inhibitory re-
ceptors are those specific for HLA-class I (HLA-I) molecules and are
represented primarily by killer Ig-like receptors (KIR) and CD94/
NKG2A. While KIR recognize allotypic determinants of classical HLA-I
molecules, CD94/NKG2A receptor recognizes the non-classical HLA-E
molecules [9]. Among the numerous activating NK receptors, a central
role for tumor or leukemia cell recognition and killing is played by
NKp46, NKp30 and NKp44 (collectively referred to as natural cyto-
toxicity receptors, NCR), NKG2D and DNAM-1 [10]. Other surface
molecules, including 2B4, NTBA and NKp80, appear to function pri-
marily as co-receptors [11–13]. Notably, also activating forms of KIR
have been documented [6]. For some of them the specificity for HLA-I
alleles has also been demonstrated [14], but their effective role in
regulating target cell recognition remains poorly clarified. The other
activating NK receptors generally recognize on target cells ligands that
are up-regulated or expressed de novo upon cell stress, tumor transfor-
mation or viral infection. While stressed healthy cells are “protected” by
their surface HLA-I molecules interacting with KIR or CD94/NKG2A,
tumor or virus-infected cells may lose HLA-I expression becoming sus-
ceptible to the NK-mediated attack [7].
As revealed by studies performed during the last decade, NK cells
belong to a new family of innate lymphoid cells (ILC). NK cells and the
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other ILC derive from a CD34+ common lymphoid progenitor and lack
receptors encoded by rearranging genes [15]. Five major groups of
lymphoid cells have been identified on the basis of the cytokines pro-
duced and the transcription factors necessary for their development.
While NK cells represent the “cytotoxic ILC” the others have been de-
fined “helper ILC” because they are non-cytolytic and produce sets of
cytokines unique for each subset. Thus, ILC1 secrete IFN-γ, ILC2 type-2
cytokines including IL-5, IL-13 and small amount of IL-4, NCR+ILC3
secrete primarily IL-22 while NCR−ILC3 (or LTi-like) produce IL-17 and
TNF-α [16,17]. Remarkably, the helper ILC mirror corresponding T
helper subsets secreting the same sets of cytokines. As a consequence,
these cytokines shape both innate and adaptive responses, although
with different timing and dynamics. Moreover, cytokines produced ei-
ther by NK cells and ILC1 (primarily IFN-γ) or by ILC2 (type 2 cyto-
kines), influence the downstream specific responses by favoring T
lymphocyte polarization towards Th1 or Th2, respectively [18].
As mentioned above, NK cells and the other ILC derive from CD34+
common lymphoid precursors that reside in the BM. However, pre-
cursors of ILC have been detected in tissues such as tonsils [19], liver
and decidua [20–27]. Moreover, the source of CD34+ precursors used
for hematopoietic stem cell transplantation (HSCT) influences the pre-
valent type of progeny (mainly NK cells vs ILC3) [28]. In addition,
drugs, including steroids [29,30] or tyrosin kynase inhibitors (Damele,
Frontiers in Immunology 2018, in press) may also cause a differential
recovery of NK cells and/or ILC3 in vitro, suggesting the possibility of
preferential growth of one or another subset in vivo. A remarkable
characteristic of ILC is their plasticity, i.e. their ability to convert into
one another as a consequence of signals delivered by the tissue mi-
croenvironment, cytokines or pathogens [16].
While the potential anti-tumor and anti-leukemia activity of NK
cells has been well documented, the actual role of other ILC is con-
troversial (see below). In addition, the particular microenvironment
established at the tumor site, may exert a complex inhibitory effect on
NK cell phenotype and function and, possibly, on ILC.
2. Effect of the tumor microenvironment on NK cell function
It is generally accepted that NK cells can eliminate tumors parti-
cularly at initial stages and also play an important role against tumor
spread and metastases [31,32]. On the other hand, the anti-tumor ac-
tivity of NK cells maybe greatly compromised in established solid tu-
mors in terms of cell numbers and efficacy [33]. It is conceivable that
NK-mediated tumor cell targeting may reflect substantial differences
between tumor cells from small initial lesions and established solid
tumors or metastases [34]. Indeed, the surface expression of HLA-I
molecules and of various ligands for activating receptors may be
downregulated or upregulated rendering different tumor cells more or
less susceptible to NK cell-mediated recognition and killing. However,
what features do have in common initial-stage and metastatic cells?
Although, they are quite distant in the process of tumor progression,
they are both relatively accessible to NK cells as they are not yet in-
cluded in an organized niche harboring and protecting cancer cells
[35]. Indeed, the presence of such a protective niche and the estab-
lishment of a tumor microenvironment are responsible not only for the
poor accessibility of different effector cells with anti-tumor potential
but also for their functional inactivation. As illustrated in previous
contributions [35,36], the tumor microenvironment contains an as-
sortment of different non-malignant cell types, including mesenchymal
stromal cells, endothelial cells, fibroblasts, macrophages and other
myeloid cells, as well as soluble factors and cytokines with inhibitory
activity released from tumor cells themselves and from non-malignant
tumor-associated (TA) cells [37–42]. These factors include the IDO-
induced kynurenin, prostaglandin E2 (PGE2), TGF-β, IL-10 [43–45]
(Fig. 1). An effect common to some of these soluble factors is the
downregulation of activating NK receptors. Thus, not only NK cells
have to face a barrier protecting tumor cells, but are also “disarmed”
and fail to recognize and kill tumor cells. Of note, hypoxia, typical of
the microenvironment of different tumors, has a similar effect, causing
downregulation of activating receptor with the remarkable exception of
CD16 [46]. Since the lytic machinery of NK cells is not substantially
compromised, mechanisms involving CD16 engagement, such as anti-
body dependent cell-mediated cytolytic activity (ADCC), are preserved
[46]. However, it should be also considered that the transcriptome
analysis of NK cells exposed to hypoxia revealed that some of their
functional capabilities, including the ability to migrate in response to
specific stimuli may be substantially modified (Parodi M. et al. Frontiers
in Immunology, 2018 in press) (Fig. 1).
NK-mediated tumor cell killing in vitro requires appropriate ratios
between NK effector and tumor target cells. However, such ratios may
not be reached, particularly in established primary or metastatic tu-
mors. In this context, when suboptimal NK/melanoma cell ratios were
tested in vitro, a paradoxical phenomenon was observed. Thus, after an
initial NK-mediated killing of tumor cells, melanoma cells became re-
sistant to lysis. This resistance reflected the increased surface expres-
sion of HLA-I molecules and a partial downregulation of NKG2D li-
gands. Both effects were consequent to IFN-γ production by NK cells. Of
note, the analysis of melanoma specimens revealed a higher HLA-I
expression on tumor cells proximal to NK cell infiltrates [47]. These
data suggest that, in some instances, NK cells may favor mechanisms of
tumor escape. Remarkably, resistance to NK cell-mediated killing in
vitro could be partially overcome by activating NK cells with IL-15 [46].
On the other hand, NK cells present in tumor-infiltrated lymph nodes of
melanoma patients may display a potent cytolytic activity against au-
tologous tumor cells, suggesting that the tumor microenvironment may
also generate/recruit a peculiar subset of highly cytolytic NK cells [48].
Another potentially harmful effect exerted by NK cells has recently
been described [49]. This refers to the epithelial-mesenchymal transi-
tion (EMT), an important mechanism that favors the metastatic dis-
semination of different tumor types. In a similar context, NK cells have
been shown to increase the aggressiveness of melanoma cells favoring
their switch from proliferative to invasive forms by inducing upregu-
lation of stemless or EMT typical markers. These effects, similar to those
induced by EMT-promoting cytokines, result in morphological changes
of tumor cells, inhibition of proliferation and increased invading ca-
pacity (Fig. 1). These changes are dependent on the engagement of
activating NK receptors and the release of IFN-γ and TNF-α. EMT in-
duction was also accompanied by the upregulation of protective HLA-I
expression on tumor cells and by the downregulation of activating NK
receptors, two effects that greatly compromise the NK-mediated tumor
cell killing. These data further indicate that NK cells, despite their
strong cytolytic potential against tumors, may be responsible of a
paradoxical effect favoring tumor escape and even inducing changes
that may lead to tumor invasion and to the initial stages of metastatic
dissemination (Fig. 1). Remarkably, however, the overall effect of NK
cells in tumor metastasis is protective, as revealed by different studies
[50]. Thus, although, in some instances, NK cells could favor me-
chanisms of tumor escape, these cells still represent a potentially reli-
able immunotherapeutic tool that may be significantly improved by the
choice of appropriate priming cytokines or the combined use of tumor
specific antibodies to exploit the NK-mediated ADCC function [33,51].
3. PD1 expression in NK cells
The inhibitory receptor PD1 functions as an important checkpoint in
the immune responses. Originally discovered by Honjo in T cells [52], it
was found to downregulate excessive T cell responses, thus contributing
to the homeostasis of the immune system. However, it became evident
that tumor cells may induce the expression of PD1 in T cells, accom-
panied by the upregulation of PD1-ligands (PD-L1 and PD-L2) on their
own surface. Thus, while under physiologic conditions PD1 functions as
a brake to avoid unwanted responses, including auto-reactivity, in
cancer it may contribute to the block of anti-tumor responses, upon
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interaction with PD-L1 (or PD-L2) –positive tumor cells. It has recently
been shown that also NK cells can express PD1, particularly those as-
sociated to tumors [53]. In this study, PD1 was first detected on small
proportions of NK cells from some healthy donors. Interestingly, all
individuals with PD1+ NK cells in their peripheral blood (PB) were
seropositive for cytomegalovirus (CMV). Analysis of patients with
ovarian carcinoma revealed that most patients had PD1+ NK cells in
their PB. More importantly, the proportions of such cells were much
higher in the ascitic fluid, strongly suggesting that the tumor environ-
ment may be responsible for the de novo expression of PD1 on NK cells.
Of note, all PD1+ cells were confined to the most mature CD56dim
CD16+ NK cells. These findings further reinforce the importance of
therapies based on anti-PD1 (or PD-L1) blocking mAbs to disrupt the
inhibitory interaction. Indeed, many metastatic carcinomas lose the
expression of HLA-I molecule, thus becoming undetectable by T cells.
However, this escape mechanism renders tumor cells susceptible to NK-
mediated killing. Thus, anti-PD1-based therapies may restore responses
to PD-L1+ tumors independent on their HLA-I surface expression levels.
In this context, determination of PD-L1 expression in tumors became a
major issue to define the eligibility for treatment with anti-PD1 or anti-
PD-L1 mAbs. These evaluations are mostly based on bioptic specimens.
Since these may provide only a partial information on the positive/
negative PD-L1 expression of given tumors, studies have been focused
to determine the number of biopsies required to more closely reflect the
PD-L1 expression status on whole tumor sections [54,55]. It is evident
that a correct information is extremely important to decide on the
eligibility of a given patient to treatment.
4. Anti-leukemia activity of NK cells in haemopoietic stem cell
transplantation (HSCT)
HSCT is the life-saving therapy for high risk acute leukemias, i.e.
leukemia either relapsing or responding poorly to chemotherapy or
with adverse cytogenetic/molecular features. Unfortunately, only for
two thirds of patients in need of HSCT a suitable HLA-compatible donor
can be found, while for the remaining patients no alternative effective
therapeutic option is available. In an attempt to rescue these patients, in
the late 90′s a new transplantation approach has been developed,
namely the HLA-haploidentical HSCT (haplo-HSCT). It is also of note
that, in the case of HSCT from a matched unrelated donor, the average
time from the diagnosis to transplantation is 2 months. As a con-
sequence, a high percentage of patients (up to 50%) succumb before
HSCT, due to their disease or infections. In contrast, in most haplo-
HSCT, a donor (a parent or a sibling) is promptly available. A crucial
graft manipulation in this highly HLA-incompatible transplant (at least
in its original setting), is the extensive T lymphocyte depletion, to avoid
the occurrence of severe GvHD. In haplo-HSCT, in the absence of T
cells, NK cells play a major role in the anti-leukemia effect. This effect
is, at least in part, associated to the NK-alloreactivity, due to a KIR-HLA
mismatch in the donor vs recipient direction. Notably, the size of the
alloreactive NK subset was found to directly correlate with a more ef-
ficient anti-leukemia effect and with the survival probability [56–58].
Fig. 1. The ambiguous functional activities of human NK cells in the tumor microenvironment.
Although NK cells play an overall positive role in defenses against tumors, their function can be drastically impaired in the microenvironment of established solid
tumors. Thus, while NK cells can kill tumor cells that have downregulated the surface expression of HLA-I surface molecules (a mechanism of tumor escape from T
cell-mediated control) (1) and can sense tumor cells that have upregulated or expressed de novo different ligands recognized by their activating receptors (2), a
number of mechanisms that impair their function may take place in the tumor microenvironment. First, the ligand themselves, if released in soluble form from tumors
may inhibit NK cell function by functioning as “decoy” ligands (3). A number of cells attracted and/or instructed by tumor cells, such as Tregs, myeloid-derived
suppressor cells (MDSC), M2-polarized macrophages release factors or cytokines that compromise the anti-tumor effect of NK cells (for example, by downregulating
the expression of activating NK receptors) (4). In some instances, even functionally important cytokines released by NK cells, such as IFN-γ and TNF-α, induce a
paradoxical effect. For example, IFN-γ can induce the upregulation on tumor cells of HLA-I molecules. HLA-I interact with KIR and NKG2A, inhibitory NK receptors,
and block NK cytotoxicity (8). IFN-γ may also induce the epithelial-mesenchymal transition (EMT), a first step of metastatic spread (5) which is also favored by the
TNF-α-induced neoangiogenesis (9). The hypoxia, frequently characterizing established tumor lesions, impairs NK cell function by downregulating the activating NK
receptors (7). Another particularly important mechanism is the expression of PD1 inhibitory receptor induced, in mature NK cells, by the tumor microenvironment.
When tumors express PD1 ligands (primarily PDL1), the PD1-PD-L1 interaction may lead to a major impairment of NK cell function. This can be restored by anti-PD1
or anti-PD-L1 mAbs, that disrupt the PD1-PD-L1 inhibitory interaction (6). These findings have important implications in the therapy of HLA-I deficient tumors which
are not susceptible to T cell-mediated control.
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This T-depleted haplo-HSCT offers also the chance of monitoring in vivo
the NK cell development from CD34+HSC [59]. Similar to in vitro
models of NK cell differentiation, the first NK cell population detectable
in PB of HSCT-recipient is CD94/NKG2A+, while KIR+ NK cells appear
in the PB after 6–8 weeks. In order to further filling the gap between
HSCT and the appearance of mature, KIR+ alloreactive NK cells derived
from donor CD34+ HSC, a novel transplantation setting has been de-
veloped [60,61]. This is based on the selective depletion of TCRαβ+ T
cells (responsible of GvHD) and B cells, so that the infused mononuclear
cells, in addition to CD34+ cells, also contain mature alloreactive NK
cells and TCRγδ+ T cells, both endowed with anti-leukemia activity
[62,63]. Thus, the prompt availability of leukemia-reactive effector
cells has further improved the clinical outcome of patients with
otherwise fatal leukemia, particularly in the case of AML for which the
haplo-HSCT using pure CD34+ could save only one third of patients.
Thus, from ∼30% and 60% overall survival probability for AML and
ALL, respectively, the percentages of patients cured with the new ap-
proach was ∼70% for both ALL and AML [61]. Taken together, these
data indicate that NK cells exert a strong anti-leukemia activity, at least
in the haplo-HSCT setting. This may be favored by the relatively low
number of blasts remaining after conditioning and their distribution in
tissues. Thus, although some IL-1-releasing AML blasts could affect NK
cell differentiation in vitro [64], it is likely that residual leukemia cells
in post-transplant patients cannot establish a suppressive tumor mi-
croenvironment. Remarkably, the ability of CD34+ precursors to give
rise also to ILC3, including the NCR−ILC3 with LTi-like activity [28],
may favor mucosal tissue repair and the organization of lymphoid ag-
gregates and secondary lymphoid organs, contributing to the recon-
stitution of the adaptive immune system, impaired by chemo/radio-
therapy during the conditioning regimen.
5. The controversial role of ILC1, ILC2, and ILC3 in tumors
While NK cells, with the few exceptions illustrated above, display an
anti-tumor activity and NK cell defects favor tumor growth (at least in
mice), the actual involvement of other ILC in tumor inhibition or pro-
motion is still contradictory [65].
Thus, ILC1, thanks to the production of IFN-γ, may polarize T cells
towards Th1 responses and macrophages towards M1, both useful for
anti-tumor responses. In addition, ILC1 induce DC maturation and favor
tumor antigen presentation through the production of TNF-α, a cyto-
kine that also promotes tumor cell apoptosis. On the other hand, IFN-γ
may induce EMT transition and metastasis and TNF-α neoangiogenesis.
Although, ILC1 secrete the same cytokines of NK cells, the anti-tumor
activity of NK cells is better defined, being related primarily to their
cytolytic activity. Along this line, the conversion of effector NK cells
into type 1 ILC have been proposed as a tumor escape mechanism in
mice [66]. ILC2, in line with type 2 responses, appear to play a pre-
valent pro-tumorigenic activity. Thus, while the induced eosinophils
may play an anti-tumorigenic activity via IL-5, ILC2-associated cyto-
kines such as IL-13 and, in part, IL-4 (produced in low amounts by
human ILC2) favor the generation of M2 macrophages, myeloid-derived
suppressor cells (MDSC), regulatory T cells (Treg) and induce Th2 po-
larization. Also ILC3 may be responsible of opposite effects on tumor
growth [16]. Thus, NCR−ILC3 induce the generation of tertiary lym-
phoid structures (TLS) which, in turn, favor T cell infiltration and re-
sponses to tumor antigens. Importantly, the frequency of TLS appears to
correlate with better prognosis in patients with lung tumors [67]. On
the other hand, the production of IL-22 (from NCR+ILC3) and IL-17
(from NCR−ILC3) may promote tumor growth. A further complexity in
defining the actual role of helper ILC in tumor immunity is related to
their plasticity. It is conceivable that ILC may contribute to shape the
tumor microenvironment; on the other hand, they may be induced to
switch in to one another. For example, IL-1β and IL-12 promote the
conversion of ILC2 into IFN-γ-producing ILC1. Moreover, conversion of
ILC1 into NCR+ILC3 can promote tumorigenesis.
6. Concluding remarks
It is now clear that different cell types that belong to the innate
immunity, particularly NK cells, play a relevant role in anti-tumor de-
fenses thanks both to their effector function and to their ability to shape
the downstream adaptive immunity towards Th1 responses which are
favorable for tumor control. On the other hand, they may also play an
unwanted role in tumor promotion, particularly under the influence of
the tumor microenvironment. Recently, it has been shown in a murine
tumor model that NK cells can recruit and interact with conventional
type 1 dendritic cells. This interaction was compromized by tumor cells,
resulting in impaired NK-mediated anti-tumor activity [68]. It is of note
that mechanisms exploited by tumors to subvert immune responses,
have a physiological role in certain normal tissue environments. For
example, the decidual environment induces NK cell inactivation/po-
larization, macrophages and other myeloid cell polarization towards a
suppressive phenotype and Treg generation [69]. The recent finding
that not only T, but also NK cells can express PD1 opened new ther-
apeutic perspectives in the cure of HLA-I-defective tumors (un-
detectable by T cells) based on the use of mAbs that target PD1 or PD-
L1. In addition, harnessing of NK cells can be achieved by blocking KIR
or NKG2A, thus overcoming the inhibitory effect consequent to their
interaction with tumors or leukemia expressing HLA-I. In this context,
in the haplo-HSCT setting, it is possible to render “alloreactive” vir-
tually all donor NK cells.
The plasticity of ILC may be exploited by inducing the preferential
generation/expansion of subsets endowed with anti-tumor activity.
This goal may be achieved by culturing CD34+ HSC with appropriate
cytokine mixtures. The resulting “useful” ILC populations may be in-
fused in new protocols of adoptive cell therapy of cancer and leukemia.
However, further investigations are clearly needed not only to find
markers that can directly identify the various ILC subsets, but also to
assess their homing properties and their ability to traffic toward dif-
ferent tumor sites.
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